Cipla’s US recovery, biosimilar pipeline key to future growth prospects
Cipla launched an initiative in a quarterly results development.
· ET Stocks, Economic Times Markets
Cipla's September-quarter earnings suffered due to a high base in its US business. The company reported sequential growth driven by its strong India business and branded prescription therapies. Recent approvals for respiratory products and a growing biosimilar pipeline bolster Cipla's optimism for future growth.
The analysis
Against that, the stock is +1.5% on the day at ₹1,378.90, and has returned -6.0% over three months. It sits 10% below its 52-week high. The pharma & healthcare sector has moved -0.9% over the same period, so Cipla is running 5.1 points behind its peers.
For Cipla, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Why it matters
- Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- In focus: Cipla (CIPLA), in Pharma & Healthcare.
- Over three months: Cipla -6.0% against Pharma & Healthcare -0.9% (5.1 points behind).
| Company | Price | Day | 1M | 3M | From 52-wk high | Volume vs 20-day | Market cap |
|---|---|---|---|---|---|---|---|
| CiplaCIPLA · Pharma & Healthcare | ₹1,378.90 | +1.5% | +2.4% | -6.0% | -10.5% | 1.3× | — |
Pharma & Healthcare
1M -0.6% · 3M -0.9%
Cipla
Prices as of 30 Oct 2026, 16:10 IST. Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Q2 Results Live: Varun Beverages Q3 Net Profit Rises 14% YoY; Reliance Slips, Sun Pharma Gains Ahead Of Earnings
Nifty Pharma index hits record high; Sun, Laurus, Zydus, Sai rally up to 6%
Max Healthcare Q2 net profit falls 15.6% on higher operating, tax expenses
Max Healthcare Q2 PAT rises 10% to ₹448 cr on higher bed occupancy
Laurus Labs shares climb 4% after Q2 profit zooms 126% YoY